Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with newly diagnosed Ewing's sarcoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Cancer and Leukaemia Group
• Treatments: Camptothecin; Irinotecan

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed Ewing's tumor

• Ewing's sarcoma or peripheral primitive neuroectodermal tumor of bone or soft tissue

• High-risk disease (R3), defined as metastases at extrapulmonary/pleural sites

• Newly diagnosed disease

• Measurable primary and/or metastatic disease

• At least one bidimensionally measurable lesion

• Concurrent enrollment on EURO-Ewing99 clinical trial required

PATIENT CHARACTERISTICS:

• No abnormal cardiac function, including any of the following:

• Fractional shortening < 29%

• Ejection fraction < 40%

• Glomerular filtration rate ≥ 60mL/min

• Not pregnant

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 3 months after completion of study treatment

• No prior or current history of chronic diarrhea, bowel obstruction, sub obstruction, Crohn's disease, or ulcerative colitis

• No other medical, psychiatric, or social condition incompatible with the study treatment

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy

• No more than 45 days since prior definitive biopsy